baber/WOPTO huggingface dataset:
Patent NZ-574108-A (NZ)
Title: Improvements in and relating to plant protection
Inventor: ROBERTS MICHAEL RICHARD
IPC: A01N37/44
Filed: 2007-07-12
Abstract: Provided is a method of treating a seed with a seed treatment composition to induce a plant resistance mechanism against one or more pests in a plant grown from said seed so as to restrict plant damage by pests, the method including applying the treatment composition to a seed, wherein the seed is a non-germinated seed, and wherein the treatment composition includes a treatment agent selected from jasmonic acid (JA) or its jasmonate salts wherein said salts are selected from the group consisting of potassium or sodium jasmonate; jasmonic acid methyl ester; jasmonic acid- L-amino acid amide-linked conjugates selected from the group consisting of the conjugate with L-isoleucine or the conjugates with L-valine, L-leucine and L-phenylalanine; 12-oxo-phytodienoic acid; coronatine; coronafacoyl-L-serine and coronafacoyl-L-threonine; methyl esters of 1-oxo-indanoylisoleucine and 1-oxo-indanoyl-leucine; coronalon; or combinations thereof, wherein the resistance mechanism is induced due to the treatment of the non-germinated seed rather than due to carry over of treatment composition from the seed onto a germinating plant.
Patent NZ-579833-A (NZ)
Title: 7-substituted indole mcl-1 inhibitors
Inventor: TAO ZHI-FU
IPC: A61K31/404
Filed: 2008-04-16
Abstract: Disclosed is an indole compound of formula (I) where the substituents are as disclosed in the specification. Examples of compounds are: 7-(3-((4-(4-Acetylpiperazin-1-yl)phenoxy)methyl)-1,5-dimethyl-1H-pyrazol-4-yl)-3-(3-(1-naphthyloxy)propyl)-1-yridine-3-ylmethyl)-1H-indole-2-carboxylic acid; 7-(2-((4-(4-carboxyphenyl)piperazin-1-yl)methyl)phenyl)-3-(3-(1-naphthyloxy)propyl)-1H-indole-2-carboxylic acid; 3-(3-(1-naphthyloxy)propyl)-7-(2-piperazin-1-ylpyridin-3-yl)-1H-indole-2-carboxylic acid; and 7-(2-(1H-imidazol-1-yl)-4-methylpyridin-3-yl)-3-(3-(1-naphthyloxy)propyl)-1-(yridin-3-ylmethyl)-1H-indole-2-carboxylic acid. Also disclosed is a composition comprising a compound of formula (I).
Patent NZ-582277-A (NZ)
Title: Syringe assembly including reuse prevention mechanism
Inventor: CAIZZA RICHARD J
IPC: A61M5/50
Filed: 2008-06-12
Abstract: Disclosed is a syringe assembly which includes a barrel with a cylindrical side wall having an inside surface defining a chamber for retaining fluid, an open proximal end and a distal end including a distal wall having a passageway therethrough in fluid communication with the chamber. The syringe assembly includes an elongate hollow plunger rod having a proximal end, an open distal end, an interior surface, and a distal lip on the distal end of the plunger rod. The syringe assembly includes a stopper at the distal end of the plunger rod. The stopper has a sealing element with a peripheral surface forming a seal with the inside surface of the barrel, and a projection extending proximally from the sealing element and forming a longitudinal recess including a distal portion. The longitudinal recess has a plurality of ramps disposed on the distal portion of the longitudinal recess and a plurality of proximal recess detents inclined outwardly in a distal direction. The syringe assembly includes a locking element with a proximal portion having a proximal edge and a distal portion having an outwardly facing barb. The locking element is positioned in the longitudinal recess so that the barb contacts the interior surface of the plunger rod and the proximal edge contacts the proximal recess detent. The plurality of ramps and the plurality of proximal recess detents on the longitudinal recess cooperate so that the distal portion of the locking element rides up the plurality of ramps to move the distal portion of the locking element outwardly towards the interior surface of the plunger rod during distal sliding movement of the plunger rod and stopper. Proximal sliding movement followed by distal sliding movement of the plunger rod and stopper within the chamber causes the barb to extend past the distal lip on the plunger rod and toward the inside surface of the barrel, preventing further proximal movement of the plunger rod with respect to the chamber.
Patent NZ-586200-A (NZ)
Title: Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
Inventor: WIDMANN RUDOLF STEFAN
IPC: A61K9/00
Filed: 2008-12-22
Abstract: Disclosed herein is the use of a cyclodextrin and/or a functional cyclodextrin derivative selected from the group consisting of á-cyclodextrin, â-cyclodextrin, ã-cyclodextrin, (2-hydroxypropyl)- â-cyclodextrin, and (sulfobutylether-7 â-cyclodextrin and mixtures thereof to increase the stability of an ultrashort-effective â-adrenoreceptor antagonist selected from the group consisting of esmolol, landiolol and flestolol or a pharmaceutically active salt thereof in a storage-stable aqueous solution suitable of parenteral administration. Also disclosed is a pharmaceutical composition for the parenteral administration of an ultrashort-effective â-adrenoreceptor antagonist in the form of a storage-stable solution essentially consisting of: · an ultrashort-effective â-adrenoreceptor antagonist selected from the group consisting of esmolol, landiolol and flestolol or a pharmaceutically active salt thereof · water; and · a cyclodextrin and/or a functional cyclodextrin derivative selected from the group consisting of á-cyclodextrin, â-cyclodextrin, ã-cyclodextrin, (2-hydroxypropyl)- â-cyclodextrin, and (sulfobutylether-7 â-cyclodextrin and mixtures thereof.
Patent NZ-591471-A (NZ)
Title: Antibodies to ccr2
Inventor: GLADUE RONALD P
IPC: A61P25/00
Filed: 2009-08-17
Abstract: Disclosed are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.
Patent NZ-592088-A (NZ)
Title: Rotary surface cleaning tool with suction extraction shoes with grooves formed across them
Inventor: STUDEBAKER ROY
IPC: A47L11/00
Filed: 2011-04-05
Abstract: A rotary surface cleaning machine 100, comprises a rotary surface cleaning tool coupled for high speed rotary motion relative to a frame member and further includes a substantially circular operational surface, and a plurality of arrays of cleaning solution delivery spray nozzles 198 angularly distributed across the operational surface of the rotary surface cleaning tool and coupled in fluid communication with corresponding liquid cleaning fluid distribution channels of a cleaning fluid distribution manifold portion of the rotary surface cleaning tool. Each of the plurality of individual arrays of cleaning solution delivery spray nozzles 198 further includes at least one or more individual delivery spray nozzles. The nozzles 198 are radially oriented across an annular portion of the substantially circular operational surface of the rotary surface cleaning tool between an inner radial limit and an outer radial limit. A plurality of suction extraction shoes 126 are angularly distributed across the operational surface of the rotary surface cleaning tool and project alternately between the arrays of cleaning solution delivery spray nozzles 198. Each of the suction extraction shoes 126 further includes a fluid extraction passage that communicate with a vacuum plenum through one of a plurality of vacuum plenum branch passages of the rotary surface cleaning tool. An operational surface of each suction extraction shoe 126 further includes a plurality of suction relief grooves 216 formed across it. The grooves 216 are substantially perpendicular to the fluid extraction passage.
Patent NZ-594583-A (NZ)
Title: Refining apparatus and method
Inventor: GRANT THOMAS PETHYBRIDGE
IPC: A61L2/10
Filed: 2011-08-15
Abstract: 594583 A refining apparatus is disclosed to reduce microbial contamination in fluids. The apparatus includes a container (1), at least one LED UV light source (3) and at least one magnetic field generator (5). The light source, magnetic field generator, and container are positioned relative to each other such that when activated the light source and magnetic field generator can act on at least the same part of the inside of the container as each other. The apparatus may be used for treating liquid fuels.
Patent NZ-594730-A (NZ)
Title: Phosphate adsorbent comprising calcium, magnesium and iron salts for the treatment of chronic kidney deficiency and/or haemodialysis patients
Inventor: WITZEL GISELA
IPC: A61K33/06
Filed: 2010-03-01
Abstract: 594730 Disclosed herein is the use of a composition comprising a physical mixture or a blend of powders, granules, crystals or crumbs of calcium salts, magnesium salts and iron salts for the preparation of a pharmaceutical composition for humans and/or animals for adsorbing phosphate in the treatment of hyperphosphataemia, in the treatment of chronic kidney deficiency (CKD) patients and/or in the treatment of haemodialysis patients.
Patent NZ-595674-A (NZ)
Title: Imidazo[2,1-b][1,3,4]thiadiazole derivatives
Inventor: PASTOR FERNANDEZ JOAQUIN
IPC: A61K31/41
Filed: 2010-04-01
Abstract: Disclosed is a compound of formula I, such as 2-(3,4-dimethoxy-phenyl)-5-(3-fluoro-4-methanesulfonyl-phenyl)-6-methyl-imidazo[2,1-b][1,3,4]thiadiazole and 5-[2-(3,4-dimethoxy-phenyl)-6-methyl-imidazo[2,1-b][1,3,4]thiadiazol-5-yl]-pyridine-2-carbonitrile, which is useful as a PI3-K inhibitor. Also disclosed is a process for the preparation of a compound of formula I.
Patent NZ-596178-A (NZ)
Title: Polymorphs of 3-(E)-2-{ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl} -3methoxyacrylate
Inventor: ZAMIR SHARONA
IPC: A01N43/54
Filed: 2008-01-16
Abstract: ABSTRACT - 596178 Disclosed herein is a crystalline polymorph Form A of (E)-2-{ 2-[6-(2-cyanophenoxy) pyrimidin-4-yloxy]phenyl} -3-methoxyacrylate characterized by at least one of the following properties: (a) the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 28 (+-0.20 DEGREE () at about 6.25, 13.8, 17.65, 19.05, 26.4, and 28.5; (b) the polymorph exhibits an infrared (IR) spectrum having characteristic peaks at about 1378, 1328 and 1154 cm-1; (c) the polymorph exhibits a Raman spectrum having characteristic peaks at about 4398, 133029 and 22332 cm-1; and (d) the polymorph exhibits a single predominant endotherm at a range of about 114-117 DEGREE C as measured by a Differential Scanning Calorimeter (DSC) at a scan rate of 10 DEGREE C per minute.
Patent NZ-597805-A (NZ)
Title: Transparent electrochromic system
Inventor: BIVER CLAUDINE
IPC: G02F1/163
Filed: 2010-07-19
Abstract: A transparent electrochromic system (100) for allowing clear vision across the system is claimed. The system comprises two parallel outer walls (10, 11) and a network of internal walls (12) placed between the two outer walls. The system is transparent for a viewing direction across the outer walls between two opposite sides. The internal walls extend perpendicularly to the outer walls and define a set of cells (13) juxtaposed in parallel to the outer Walls. Portions of liquid and/or gel are contained respectively in the cells (13) and first and second electroactive substances are distributed in the· portions of liquid and/or gel, with respective electrical redox potentials that are different. At least some of the first and second electro active substances have a variable optical effect between an oxidized form and a reduced form of the substances. The system further comprises two transparent power supply electrodes (1, 2) carried together by a single one (10) of the two outer walls, and intended to be connected respectively to two power supply terminals of a variable electrical power supply unit(20, 21). Each of the power supply electrodes is in direct electrical contact with the portions of liquid and/or gel contained in at least some of the cells (13) for transferring electrons to or from at least some of the electroactive substances, in an inverse way between the first and second electroactive substances at a given time. The system further comprises at least one additional transparent electrode (3) without direct electrical contact with the power supply electrodes (1, 2) inside the electrochromic system. The additional electrode is parallel to the power supply electrodes inside at least some of the cells (13).
Patent NZ-598469-A (NZ)
Title: Safety valve for an automatic dairy animal milking unit with piston movable between miking position and backflush position
Inventor: TORGERSON KEVIN L
IPC: A01J7/02
Filed: 2010-09-03
Abstract: 598469 A safety valve (60) for a milker unit backflush system is disclosed. The safety valve (60) comprises a housing defining a milk inlet (62), a milk outlet (64), a milk passage extending between the inlet and the outlet, a backflush fluid inlet (186) and a backflush fluid conduit extending between the backflush inlet and the milk inlet. A first seal (96) is mounted in the backflush conduit and a second seal (94) is mounted in the milk passage. A backflush piston (120) is disposed in the housing for movement between a milking position in which the backflush piston (120) engages the first seal (96) and a backflush position in which the backflush piston (120) engages the second seal (94).
Patent NZ-600705-A (NZ)
Title: Tilting device for a chair
Inventor: MEYER STEFAN
IPC: A47C3/025
Filed: 2010-11-10
Abstract: 600705 Disclosed is a tilting device (5) suitable for a chair. The chair comprises a base and a gas (2) spring and a seat plate (3) extending vertically upwards. The tilting device (5) is disposed between the base and the seat plate (3). The seat plate (3) comprises an elastic body (8) wherein the bottom and top sides are fixedly connected to a rigid plate (6, 7). The bottom plate (6) has a bulge (9) which is partially conically embodied extending vertically upwards. The tilting device (5) can be pushed onto the upper end of the gas spring (2). A pivot lever actuates the gas spring (2).
Patent NZ-606809-A (NZ)
Title: Fiber structure, method for its manufacture and use as well as fiber-resin composite material
Inventor: RALF HOPPE
IPC: E04C5/07
Filed: 2013-02-08
Abstract: A fiber-resin composite material containing at least one thermosetting resin as well as at least one fixed and/or stabilized fiber structure from a fibrous material selected from the group comprising: • glass fibers, • carbon fibers, • mineral fibers, • synthetic fibers, mixtures thereof; and an agent for its fixing and stabilizing, wherein the agent for fixing and stabilizing is at least one statistical copolyester which is formed from the following components: from 55 to 100 mol% terephthalic acid; from 0 to 45 mol% isophthalic acid; from 35 to 75 mol% butanediol: from 15 to 35 mol% diethylene glycol; from 10 to 30 mol% triethylene glycol, wherein the sum of the molar fractions of terephthalic acid and butanediol is a maximum of 150 mol% with respect to the total diacid and total diol quantities of 100 mol% each.
Patent NZ-611743-A (NZ)
Title: Dissolvable tobacco film strips and method of making the same
Inventor: MARUN MARIA CAROLINA
IPC: A23L27/00
Filed: 2007-05-25
Abstract: The disclosure relates to a method of making a dissolvable tobacco film strip comprising the steps of: forming a mixture of at least one tobacco component, at least one binder and at least one humectant, wherein the at least one tobacco component comprises shredded, ground and/or powdered tobacco, the binder comprises pullulan, cellulose ethers, sodium alginate, pectin, gums or mixtures thereof and the humectant comprises one or more of polyhydric alcohol and aliphatic ester of mono-, di- or polycarboxylic acid; casting or extruding the mixture to form a film; drying the film; and forming the film into film strips, the tobacco content of the film strip being at least 50% by weight, the binder content of the film strip being from 3% to 12% by weight and the humectant content of the film strip being from 20 to 40% by weight. These consumable tobacco film strips are adapted to dissolve in the oral cavity and provide tobacco satisfaction.
Patent NZ-612119-A (NZ)
Title: Use of sigma ligands in bone cancer pain
Inventor: VELA HERNÁNDEZ JOSÉ MIGUEL
IPC: C07D231/18
Filed: 2011-12-02
Abstract: The disclosure relates to the use a sigma ligand for the manufacture of a medicament for use in the prevention and/or treatment of bone cancer pain. The pain may be selected from acute and/or chronic pain developed as a consequence of bone cancer, preferably neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure. The sigma ligand may have a structure according to structural formula (I), wherein, R1, R2, R3, R4, R5, R6 and n are as defined within the specification and the ligand may be combined with at least one opioid or opiate compound. Example compounds include: 4-{ 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl} morpholine, 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine, 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole, 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole, 1-{ 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl} piperidine, 4-{ 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]butyl} morpholine, 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole, 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine, N-benzyl-4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-methylbutan-1-amine, 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1-amine.
Patent NZ-613970-A (NZ)
Title: Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
Inventor: LEUTHNER BRIAN A
IPC: A61K38/16
Filed: 2012-02-13
Abstract: Disclosed is a use of a microparticulate formulation of a therapeutic agent, wherein the microparticulate formulation comprises a plurality of microparticles and the therapeutic agent comprises a dihydropyridine L-type voltage dependent calcium channel inhibitor selected from the group consisting of nisolipine, nicardipine, difedipine and nimodipine, and a pharmaceutically acceptable carrier comprising between 0% to 5% hyaluronic acid in the manufacture of a medicament for treating a delayed complication associated with a brain injury in a mammal in need thereof, wherein the brain injury includes interruption of at least one cerebral artery in subarachnoid space, wherein the medicament is a site-specific, sustained release pharmaceutical composition and is for use in a dosage regime comprising: (a) administering a therapeutic amount of the pharmaceutical composition locally by a means for administration of the therapeutic amount of the pharmaceutical composition at a site of administration, wherein: (1) the microparticulate formulation of the pharmaceutical composition is flowable; (2) the microparticles are of uniform size distribution; (3) each microparticle comprises a matrix; (4) the L-type voltage dependent calcium channel inhibitor is dispersed throughout each microparticle; (5) the L-type voltage dependent calcium channel inhibitor is released from the microparticulate formulation by gradual release over an extended period of time; (6) cerebrospinal fluid (CSF) concentration of the L-type voltage dependent calcium channel inhibitor remains in therapeutic range while plasma concentration of the L-type voltage dependent calcium channel inhibitor is below therapeutic range during therapy, thereby circumventing unwanted side effects associated with systemic delivery; and (7) the therapeutic amount that contacts and flows around the cerebral artery in the subarachnoid space is effective in reducing signs or symptoms of at least one delayed complication associated with the brain injury, wherein the at least one delayed complication is delayed cerebral ischemia (DCI), comprising a plurality of microthromboemboli, a cortical spreading ischemia (CSI), and an angiographic vasospasm, or a combination thereof.
Patent NZ-618707-A (NZ)
Title: Oxygen compressor with boost stage
Inventor: GOERTZEN GEROLD
IPC: A61M16/00
Filed: 2012-05-23
Abstract: An oxygen concentration and compression system includes an oxygen concentrator, a boost stage, a compressor, and a portable container. The boost stage receives oxygen enriched gas at a first pressure from the oxygen concentrator. The boost stage includes a pressure increasing device that increases the pressure of the oxygen enriched gas from the first pressure to a second, controlled pressure. The compressor receives the oxygen enriched gas at the second, controlled pressure and compresses the oxygen enriched gas to a third pressure in the portable container for later use by a patient. A patient outlet provides oxygen enriched gas from the oxygen concentrator or the boost stage for use by a patient.
Patent NZ-622751-A (NZ)
Title: Anchor bolt
Inventor: ANTHONY JON STEWART FUTTER
IPC: F16B33/02
Filed: 2014-03-20
Abstract: Disclosed is an anchor bolt (1). Anchor bolts are difficult to remove from masonry, as while the part of the bolt extending from the masonry is easily removed the remainder of the bolt remains within the masonry. Over time, the part of the bolt which remains within the masonry can lead to corrosion damaging the masonry. The disclosed bolt may be more easily removed by rotating an additional nut. The anchor bolt (1) comprises an inner bolt (3); an inner bolt nut (7); outer sleeve (5) and sleeve nut (9). The inner bolt (3) has an externally threaded portion (3a) at or adjacent a first end and a flared second end (3b). The inner bolt nut (7) engages with the externally threaded portion (3a) of the inner bolt (3). The outer sleeve (5) receives the inner bolt (3). The outer sleeve (5) has an externally threaded portion at or adjacent a first end and a radially expandable portion (5c) at a second end (5b). The sleeve nut (9) engages with the externally threaded portion of the outer sleeve (5). The inner bolt (3), inner bolt nut (7) and outer sleeve (5) are arranged such that as the inner bolt (3) is rotated, the inner bolt (3) is drawn through the outer sleeve (5) and the flared second end (3b) expands the radially expandable section (5c) of the outer sleeve (5). The outer sleeve (5) and outer sleeve nut (9) are arranged such that as the outer sleeve nut (9) is rotated, the outer sleeve (5) is drawn through the outer sleeve nut (9) in a direction away from the flared second end (3b) of the inner bolt (3).